title: Biosimilars advancements: Moving on to the future.
abstract: Many patents for the first biologicals derived from recombinant technology and, more recently, monoclonal antibodies (mAbs) are expiring. Naturally, biosimilars are becoming an increasingly important area of interest for the pharmaceutical industry worldwide, not only for emergent countries that need to import biologic products. This review shows the evolution of biosimilar development regarding regulatory, manufacturing bioprocess, comparability, and marketing. The regulatory landscape is evolving globally, whereas analytical structure and functional analyses provide the foundation of a biosimilar development program. The challenges to develop and demonstrate biosimilarity should overcome the inherent differences in the bioprocess manufacturing and physicochemical and biological characterization of a biosimilar compared to several lots of the reference product. The implementation of approaches, such as Quality by Design (QbD), will provide products with defined specifications in relation to quality, purity, safety, and efficacy that were not possible when the reference product was developed. Actually, the need to prove comparability to the reference product by the biosimilar industry has increased the knowledge about the product and the production-process associated by the use of powerful analytical tools. The technological challenges to make copies of biologic products while attending regulatory and market demands are expected to help innovation in the direction of attaining more productive manufacturing processes.
authors.affiliation: Lab. Biofármacos em Células Animais do Instituto Butantan, São Paulo, SP, 05503-900, Brazil.
authors.forename: Lilian Rumi
authors.initials: LR
authors.lastname: Tsuruta
authors.affiliation: Lab. Biofármacos em Células Animais do Instituto Butantan, São Paulo, SP, 05503-900, Brazil.
authors.forename: Mariana
authors.initials: M
authors.lastname: Lopes dos Santos
authors.affiliation: Lab. Biofármacos em Células Animais do Instituto Butantan, São Paulo, SP, 05503-900, Brazil.|iii/INCT-Instituto de Investigação em Imunologia, USP, São Paulo, SP, Brazil.
authors.forename: Ana Maria
authors.initials: AM
authors.lastname: Moro
mesh_terms: D000818:Animals; D059451:Biosimilar Pharmaceuticals; D001709:Biotechnology / Q000639:trends*; D004195:Disease Models, Animal; D004345:Drug Industry / Q000191:economics / Q000639:trends*; D006801:Humans
chemical_list: D059451:Biosimilar Pharmaceuticals
keywords: bioassays; biosimilars; comparability; high-order structure; monoclonal antibodies